The Number of Harvested LNs Is an Independent Prognostic Factor in Lymph Node Metastasis-negative Patients Who Received Curative Esophagectomy.
Esophageal cancer
lymph node
recurrence
survival
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
12
04
2020
revised:
17
04
2020
accepted:
18
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
The aim of the present study was to evaluate the optimal number of harvested LNs (LNs) in patients who were LN metastasis-negative after curative esophagectomy for esophageal cancer. Sixty-one patients who underwent curative surgery for esophageal cancer between 2005 and 2017 and diagnosed as lymph node metastasis-negative were included in this study. The 5-year overall survival rates were 27.8% for 0-20 harvested LNs, 35.7% for 21-30 harvested LNs, 79.4% for 31-40 harvested LNs, and 85.2% for ≥41 harvested LNs. Thirty harvested LNs was regarded as the optimal critical point of classification, considering the 5-year OS rate. The number of harvested LNs was selected as a significant prognostic factor in both univariate and multivariate analyses. The respective 3- and 5-year OS rates were 50.3% and 36.7% for <30 harvested LNs and 82.4% and 82.4% for ≥30 harvested LNs (p=0.003). Thirty or more harvested LNs was a significant prognostic factor in patients with metastasis-negative LNs after curative esophagectomy for esophageal cancer. Therefore, the number of harvested LNs might be useful for predicting the LN metastasis status in esophageal cancer.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The aim of the present study was to evaluate the optimal number of harvested LNs (LNs) in patients who were LN metastasis-negative after curative esophagectomy for esophageal cancer.
PATIENTS AND METHODS
METHODS
Sixty-one patients who underwent curative surgery for esophageal cancer between 2005 and 2017 and diagnosed as lymph node metastasis-negative were included in this study.
RESULTS
RESULTS
The 5-year overall survival rates were 27.8% for 0-20 harvested LNs, 35.7% for 21-30 harvested LNs, 79.4% for 31-40 harvested LNs, and 85.2% for ≥41 harvested LNs. Thirty harvested LNs was regarded as the optimal critical point of classification, considering the 5-year OS rate. The number of harvested LNs was selected as a significant prognostic factor in both univariate and multivariate analyses. The respective 3- and 5-year OS rates were 50.3% and 36.7% for <30 harvested LNs and 82.4% and 82.4% for ≥30 harvested LNs (p=0.003).
CONCLUSION
CONCLUSIONS
Thirty or more harvested LNs was a significant prognostic factor in patients with metastasis-negative LNs after curative esophagectomy for esophageal cancer. Therefore, the number of harvested LNs might be useful for predicting the LN metastasis status in esophageal cancer.
Identifiants
pubmed: 32606176
pii: 34/4/2021
doi: 10.21873/invivo.12001
pmc: PMC7439900
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2021-2027Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Anticancer Res. 2018 Mar;38(3):1569-1577
pubmed: 29491087
Cancer Manag Res. 2020 Feb 20;12:1269-1279
pubmed: 32110101
J Gastrointest Surg. 2017 May;21(5):867-878
pubmed: 28251467
J Clin Oncol. 2001 Apr 1;19(7):1970-5
pubmed: 11283129
Am J Clin Oncol. 2019 Dec;42(12):924-931
pubmed: 31651453
Br J Surg. 2019 Sep;106(10):1298-1310
pubmed: 31216064
Ann Surg Oncol. 2020 Jun;27(6):2042-2050
pubmed: 31898102
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Dis Esophagus. 2008;21(6):488-95
pubmed: 18840133
Oncol Lett. 2018 Nov;16(5):6705-6712
pubmed: 30405812
Gen Thorac Cardiovasc Surg. 2013 Jun;61(6):330-5
pubmed: 23568356
Thorac Cancer. 2019 May;10(5):1149-1157
pubmed: 30957414
Open Med (Wars). 2020 Mar 08;15:152-159
pubmed: 32190739
Ann Oncol. 2019 Jan 1;30(1):34-43
pubmed: 30475943
Ann Oncol. 2016 Sep;27(suppl 5):v50-v57
pubmed: 27664261
Ann Thorac Surg. 2010 Sep;90(3):908-13
pubmed: 20732516
J Surg Oncol. 2012 Nov;106(6):742-7
pubmed: 22504922
Cancer. 2008 Mar 15;112(6):1239-46
pubmed: 18224663
Br J Surg. 2020 May;107(6):647-654
pubmed: 32108326
J Thorac Dis. 2017 Jul;9(Suppl 8):S731-S740
pubmed: 28815069